Pfizer’s strategic move to revise its bid for Metsera underscores its dedication to advancing next-generation obesity therapies and fostering competition in the global pharmaceutical landscape.

In a major development in the global pharmaceutical industry, Pfizer has taken a decisive step to strengthen its position in the race for Metsera, an emerging leader in obesity drug development.

The U.S. pharmaceutical giant announced that it has removed certain conditions from its initial bid, signaling greater flexibility and commitment to finalizing the merger.

This move comes as Pfizer seeks to outpace rival bidder Novo Nordisk, which recently made a competing $10 billion offer for the innovative biotech company.

The decision, revealed in a letter filed in Delaware, highlights Pfizer’s strategic focus on expanding its presence in the fast-growing obesity treatment market—a sector projected to reach over $100 billion by 2030.

By simplifying the terms of its proposal, Pfizer aims to demonstrate its long-term confidence in Metsera’s scientific potential and its readiness to collaborate with the company’s leadership to accelerate groundbreaking metabolic health therapies.

According to Pfizer, the revised proposal eliminates conditions related to direct stock sales and public disclosures, making the acquisition process smoother and more transparent.

The company emphasized that its offer is designed not only to strengthen shareholder value but also to preserve Metsera’s research autonomy and innovative culture.

This approach marks a notable shift toward cooperative growth rather than a traditional corporate takeover.

Pfizer’s renewed commitment comes at a crucial time for the company, which has been strategically realigning its portfolio following the pandemic.

After experiencing fluctuations in COVID-19 vaccine revenues, Pfizer has turned its focus toward high-growth therapeutic areas such as obesity, cardiovascular health, and oncology.

The acquisition of Metsera would represent a major leap in this direction, granting Pfizer access to a promising pipeline of next-generation weight management and metabolic drugs.

Industry analysts view this move as a positive and forward-thinking strategy that positions Pfizer as a serious contender in a market currently dominated by Novo Nordisk and Eli Lilly.

Obesity treatment has rapidly become one of the most dynamic segments in pharmaceuticals, with new drug classes offering not just weight loss benefits but also improved cardiovascular and metabolic outcomes.

Pfizer’s interest in Metsera aligns with its broader mission to develop holistic health solutions that go beyond symptom management and address underlying disease mechanisms.

Beyond business strategy, Pfizer’s pursuit of Metsera also underscores its belief in fostering scientific collaboration and expanding patient access to cutting-edge therapies.

Company representatives have emphasized that their vision for the merger includes leveraging Pfizer’s global scale and regulatory expertise while maintaining Metsera’s innovative research environment.

This synergy could accelerate clinical development timelines and make advanced obesity treatments available to millions worldwide sooner than expected.

While Novo Nordisk’s bid has added competitive tension to the acquisition process, Pfizer’s decision to revise its offer reflects resilience and adaptability—qualities that have long defined the company’s approach to research and partnerships.

Market observers suggest that Pfizer’s proactive adjustments could appeal to Metsera’s board, which is tasked with balancing shareholder value against long-term strategic fit.

If successful, the acquisition could signal a new era of collaboration in obesity research, combining Pfizer’s established global infrastructure with Metsera’s pioneering drug development expertise.

Such a partnership could potentially unlock new treatment options for metabolic diseases that affect more than a billion people globally.

The company’s leadership has reiterated that this move is not merely about expanding Pfizer’s portfolio but about driving positive change in global healthcare.

By focusing on inclusivity, innovation, and scientific excellence, Pfizer hopes to lead the next wave of medical breakthroughs in metabolic health and chronic disease prevention.

As the Delaware court reviews the matter, Pfizer remains optimistic that its revised proposal demonstrates a fair, forward-looking vision for both companies.

The outcome of this bid could redefine the competitive landscape in obesity therapeutics and serve as a case study in how pharmaceutical giants are adapting to meet the evolving needs of patients and markets worldwide.

With this bold and positive move, Pfizer has once again shown that innovation and flexibility remain at the heart of its mission—delivering transformative solutions for patients, shareholders, and the future of global healthcare.

The analysis of almost 1.2 million people by Israel’s largest healthcare provider will offer further hope for countries as they get shots into citizens’ arms, particularly those considered vulnerable, and curb the pandemic that has killed more than 3.1 million people.

The vaccine was 80% effective against symptomatic infection for people with heart or chronic kidney diseases, 86% for people with type 2 diabetes, 75% for cerebrovascular disease, and 84% for people suffering from immunodeficiency, according to the Clalit Research Institue study.

For people who were vaccinated and were already suffering three or more chronic conditions or risk factors, such as heart disease, neurological disease, chronic kidney disease, chronic lung disease, smoking, pregnancy or obesity, the research shows it was 88% effective in preventing symptomatic infection.

It was more than 90% effective against severe disease for people with type 2 diabetes, heart or cerebrovascular disease and 100% for people suffering from immunodeficiency.

The data is the latest from Israel where a universal and digitised healthcare system and the speedy vaccination programme have allowed researchers insights into the vaccine’s potency. Clalit covers more than half of Israel’s population.

The results were lower than the 96% overall vaccine effectiveness seven days or more after the second dose, found by the study and the 95% effectiveness found in clinicial trials last year.

But researchers said they offered some optimism that the vaccine still offers protection against severe illness in people who become infected after they get their shots.

“Protection is mildly reduced among patients with several co-morbidities. These results are very encouraging, as they suggest that most COVID-19 cases will be prevented by vaccination even in the elderly and chronically ill,” said Ran Balicer, Clalit’s chief innovation officer.

“People with chronic diseases, multiple chronic or severe chronic diseases, should get vaccinated because the vaccine is very effective in protecting them against the high rates of complications that are expected,” Balicer said.

The research was also carried out by Harvard and the University of Michigan and published in the New England Journal of Medicine on Thursday.

The Clalit study, compared 596,618 people vaccinated between Dec. 20 2020 and Feb. 14 against the same size group of unvaccinated people, matching age, gender and other characteristics.

The subgroup of the people with chronic diseases was about 130,000 people, Balicer said.

More than half of Israel’s 9.3 million population has been fully inoculated since its vaccination drive began in late December. COVID-19 cases have dropped continuously since a mid-January peak as the economy has largely opened.

Until mid-April, Israel has documented 98% fewer coronavirus cases, 93% fewer critically ill and 87% fewer COVID-19 deaths, according to Eran Segal, data scientist at the Weizmann Institute of Science.

Balicer said that although Israel was not yet at “herd immunity,” the sharp drop was “proof of the potential of mass vaccination to really take us out of harm’s way and shows the light at the end of the tunnel”.

Obesity, Hypertension and Overweight

The large sample size allowed researchers to look more closely at subgroups of people with specific chronic diseases which would not necessarily be examined in a vaccine clinical trial, the researchers said.

It also found the vaccine to be 92% effective in preventing symptomatic COVID-19 among people over the age of 70, 96% for overweight people and 93% for those suffering obesity and provided 90% protection for people suffering from hypertension.

Danny Altmann, an immunology professor at the Imperial College London, said the study was among the first real world research to offer such granular data into vaccinated subgroups.

“Transitioning into real-world application, the effectiveness still looks terrific, but inevitably there are people who make poor vaccine responses,” he said in an email to Reuters.

“We need to know who they are, why, and what can be done to rescue immunity. Next, we need to see the results from each of the big cohort studies for the various patient groups.”

The U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said that of the 84 million people who have been fully vaccinated in the United States, fewer than 6,000 have got sick with COVID-19 more than two weeks after being fully dosed.

Of those, nearly 400 were hospitalised and around 75 died, according to CDC data. Some of the hospitalisations and deaths were not due to COVID-19 infections.

Pfizer’s late-stage clinical trial included people with co-morbidities. The most frequently reported co-morbidities were obesity (35.1%), diabetes (with and without chronic complications, 8.4%) and pulmonary disease (7.8%), a spokesman said.

The surge of distrust increased, and ordinary Iranians got angry again.  

Unfulfilled promises of Iranian officials about the homegrown vaccine against COVID-19, the low vaccination rate of Iranians, the high toll rate, along economic problems and crippling sanctions have caused a frustrating situation for Iranians. Perhaps during these difficult times, only the pain of COVID-19 vaccine injection could soothe other pains of Iranians. Iranians are still waiting to receive the vaccine, and their eyes are staring regrettably at the vaccination program of other countries.

COVID-19 began to spread in Iran more than a year ago, and since then, many Iranians have been affected heavily by the disease and suffered during this period. Approximately 1.8 million Iranians have been infected with the virus and nearly 62,000 have died of COVID-19 as of March 28, but many analysts say that the pandemic’s death toll in Iran is three to four times higher than the official figure. 

Since August 2020 when the first news of production of the COVID-19 vaccine was published by Russia, Iranians like other nations became hopeful to protect themselves by vaccination. Also, several vaccines have been produced and many countries started their vaccination programs. In Iran, the vaccination program commenced on 9 February 2021, but the country dropped behind other countries around the world. According to Our World in Data, in vaccination competition in the Middle East, many countries such as U.A.E, Qatar, Saudi Arabia, and Kuwait are above Iran in terms of COVID-19 vaccine doses administered per 100 people. In addition, the number of people that have received two doses of the COVID-19 vaccine in Iran who are known as fully vaccinated people is under 650,000 optimistically, and it is a disaster in comparison to other countries in the world. For instance, the current population of Iran is nearly 85 million; as a result, under 0.8 percent of Iranians have fully vaccinated against COVID-19 by the Iranian government while Turkey, in the neighborhood of Iran, which roughly has the same number of people as Iran, has fully vaccinated 7.1 percent of its population. 

“We have invested in the infrastructure to produce homegrown vaccines, and we will produce 1.5 million doses of inactivated COVID-19 vaccine up to the next one month. If we go according to the planning, we can supply the demand of Iran against COVID-19 disease,” said Hamidreza Jamshidi, Secretary of National Anti-Coronavirus Headquarters on Iranianstate television in December 2021. Also, Mohammad Mokhber, Head of the Headquarters for Executing the Order of Imam Khomeini as an organization under the direct control of the Iranian supreme leader stated at the same time that “we can produce 1.5 million doses of Covid-19 vaccine up to the next 40 days, and our vaccine production capacity against COVID-19 would reach 12 milliondoses up to the next 6 months. After supplying the demand of Iran; we can export vaccines around the world.” 

But now in March 2021, the global sources say nearly 125,000 doses of the COVID-19 vaccine have been administered in Iran as 0.2 per 100 people while according to the official figure of Iran, about 1 million people have been vaccinated against the COVID-19 so far. Clearly, the Iranian official’s promises about producing homegrown COVID-19 vaccines have not been realized as of yet; therefore, the officials have promised again that the homegrown vaccines would be available for the public vaccination program on May 22, 2021. 

The Iranian government injected hope into people instead of vaccines by promises of producing homegrown vaccines when the Iranian supreme leader banned the import of COVID-19 vaccines the U.S and the UK. According to the Iranian officials, COV-Iran Barekat, Razi CovPars, and Fakhra are the Iranian COVID-19 vaccines which would be available over the next four months, but many Iranians are distrustful of homegrown vaccines. 

The distrust comes from Iranian official’s contradictory statements about the time of using the Iranian vaccines. The internal product against COVID-19 as Mostaan is another reason for distrusting. Mostaan is the questionable device that was unveiled in April 2020 by the Islamic Revolutionary Guard Corps. The IRGC’s Commander-in-Chief Hossein Salami claimed that the device can be used to detect moments of the COVID-19 within a 100 m (330 ft) radius based on electromagnetic radiation. The device is not used to fight COVID-19 in public up to now, and many questions about its usage have remained in public opinion. Another reason for distrust is the discriminatory background of the way distribution of vaccines in Iran. In September 2020, when ordinary Iranians were looking for the orphan influenza vaccine, 1,500 doses were allocated to the Iranian parliament. The unfair measure made many Iranians angry, and the public pressure resulted in the Iranian parliament returning the vaccines. Furthermore, many letters have been published recently in cyberspace to give priority to a number of social classes in the vaccination program. In one of them, an official from the Ministry of Health and Medical Education of Iran had asked that actors and artists should be prioritized in the vaccination program. Following the letter, the surge of distrust increased, and ordinary Iranians got angry again.  

Long-term waiting for vaccination and distrusting of people of officials have caused the nervous reactions in cyberspace. Many Iranians abroad have published their picture while they are receiving the COVID-19 vaccine, and these pictures have caused the anger of many Iranians inside the country. Seyyed Shahab Hosseini is an Iranian actor that received a Pfizer-BioNTech vaccine in February 2021 in the U.S. The publishing pictures of his injection showed people are sensitive to strange delays in vaccination because many people attacked him in cyberspace. Consequently, the criticisms on social media led to Hosseini deactivating his Instagram account.

Vaccination in Iran must speed up by using a homegrown vaccine or foreign vaccine. Iranians are under crippling economic sanctions that were re-imposed by the Trump administration. And the US President Joe Biden has not lifted the sanctions against Iran. The price of food products is higher than at any time since the 1979 revolution. In such circumstances, the World Health Organization and powerful countries should help Iran more. Today, Iranians have to suffer the pain of the sanctions, the economic problems, and the vulnerability to the COVID-19. The pain of the injection of the vaccine could soothe all their pains. Iranian people are still waiting to receive the vaccine and look regrettably at the vaccination program of other countries.

Mohammad Javad Mousavizadeh is a journalist and analyst in international affairs and foreign policy. He has written many articles for digital publications around the world such as Khabar Online News Agency, Foreign Policy News, The Levant News, Eastern Herald, Modern Diplomacy, and South Front.